Literature DB >> 12116027

Reactivation of human herpesvirus 6 and 7 in pregnant women.

Masahiro Ohashi1, Tetsushi Yoshikawa, Masaru Ihira, Kyoko Suzuki, Sadao Suga, Shin Tada, Yasuhiro Udagawa, Hisataka Sakui, Keiji Iida, Yumiko Saito, Yukihiro Nisiyama, Yoshizo Asano.   

Abstract

To elucidate the roles of human herpesvirus (HHV)-6 and -7 in pregnant women, peripheral blood samples and genital tract secretions were collected serially from pregnant women, and both serological testing and polymerase chain reaction (PCR) were carried out to detect viral DNA in the secretions. HHV-6 or HHV-7 Immunoglobulin(Ig)M antibodies were not detected in 432 plasma samples collected from pregnant women and cord blood, but IgG antibodies against both viruses were detected in all plasma samples. Significant increases in HHV-6 and HHV-7 IgG antibodies were observed in two (1.6%) and three (2.4%) pregnant women respectively of a total of 123 cases. HHV-6 DNA was detected in the genital tract in three (3.7%) of 82 pregnant women at the first trimester, and in 10 (12.2%) of the same women in the third trimester. The detection rate in the third trimester was significantly higher than that in the first trimester (P = 0.043). Although HHV-7 DNA was detected in the genital tract of two (2.7%) and seven (9.6%) pregnant women of a total of 73 during the first and third trimesters respectively, there was no statistical difference in the detection rate of the viral DNA between the trimesters. Because a significant increase in HHV-6 IgG antibodies was detected in only two pregnant women, it was not possible to carry out statistical analysis to determine the relationship between HHV-6 infection and associated clinical features. Although there was a significant increase in HHV-7 antibody titers in three pregnant women, a positive correlation between the virus infection and the clinical features was not demonstrated. There was no statistical association between virus shedding in the genital tract and the clinical features examined in this study. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116027     DOI: 10.1002/jmv.10083

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Pregnancy and human herpesvirus 8 reactivation in human immunodeficiency virus type 1-infected women.

Authors:  Andrea Lisco; Massimo Barbierato; Josè R Fiore; Paola Gasperini; Anna Favia; Anna Volpe; Maria Chironna; Giuseppe Pastore; Luigi Chieco-Bianchi; Maria Luisa Calabrò
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

Review 2.  Heterogeneous pathways of maternal-fetal transmission of human viruses (review).

Authors:  A Saleh Younes; Márta Csire; Beatrix Kapusinszky; Katalin Szomor; Mária Takács; György Berencsi
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

Review 3.  Pityriasis rosea in pregnancy: report of a spousal occurrence and craniosynostosis in the healthy newborn.

Authors:  Tiffany Y Loh; Philip R Cohen
Journal:  Dermatol Pract Concept       Date:  2016-07-31

Review 4.  Is the ZIKV Congenital Syndrome and Microcephaly Due to Syndemism with Latent Virus Coinfection?

Authors:  Solène Grayo
Journal:  Viruses       Date:  2021-04-13       Impact factor: 5.048

Review 5.  Human Herpesviruses 6A and 6B in Reproductive Diseases.

Authors:  Anthony L Komaroff; Roberta Rizzo; Jeffrey L Ecker
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

Review 6.  Maternal natural killer cells at the intersection between reproduction and mucosal immunity.

Authors:  Evgeniya V Shmeleva; Francesco Colucci
Journal:  Mucosal Immunol       Date:  2021-04-26       Impact factor: 7.313

7.  Presence of HHV-6A in Endometrial Epithelial Cells from Women with Primary Unexplained Infertility.

Authors:  Roberto Marci; Valentina Gentili; Daria Bortolotti; Giuseppe Lo Monte; Elisabetta Caselli; Silvia Bolzani; Antonella Rotola; Dario Di Luca; Roberta Rizzo
Journal:  PLoS One       Date:  2016-07-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.